VU LSC-EMBL Partnership Institute for Genome Editing Technologies, Life Sciences Center, Vilnius University, LT-10257 Vilnius, Lithuania.
Institute of Biochemistry, Life Science Center, Vilnius University, LT-10257 Vilnius, Lithuania.
Cells. 2023 Oct 16;12(20):2466. doi: 10.3390/cells12202466.
Hyperlipidemia is a medical condition characterized by high levels of lipids in the blood. It is often associated with an increased risk of cardiovascular diseases such as heart attacks and strokes. Traditional treatment approaches for hyperlipidemia involve lifestyle modifications, dietary changes, and the use of medications like statins. Recent advancements in genome editing technologies, including CRISPR-Cas9, have opened up new possibilities for the treatment of this condition. This review provides a general overview of the main target genes involved in lipid metabolism and highlights the progress made during recent years towards the development of new treatments for dyslipidemia.
高脂血症是一种血液中脂质水平升高的医学病症。它通常与心血管疾病（如心脏病发作和中风）的风险增加有关。高脂血症的传统治疗方法包括生活方式改变、饮食改变和使用他汀类药物等药物。最近，基因组编辑技术（包括 CRISPR-Cas9）的进步为这种疾病的治疗开辟了新的可能性。本文综述了参与脂质代谢的主要靶基因，并重点介绍了近年来在开发治疗血脂异常的新疗法方面所取得的进展。
Zotero 插件